Currently, several strategies have been developed for HER2-altered cancers (Fig. 2) such as ADCs which precisely deliver cytotoxic warheads to kill cancer cells directly as well as exert bystander-killing effect against tumor microenvironment cells. Here, ERBB2 is linked to cancer.